ReviewMolecules (Basel, Switzerland)2022
The Kynurenine Pathway and Kynurenine 3-Monooxygenase Inhibitors.
Review in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 83 citations in OpenAlex.
- Kynurenine pathway dysregulation in attention-deficit hyperactivity disorder: Impact on N-methyl-D-aspartate receptors and phasic dopamine maturation.World journal of clinical pediatrics · 2026Review
- KMO deletion preserves non-associative learning and SVZ neurogenesis in aging mice.Behavioural brain research · 2026Article
- Molecular mechanisms and therapeutic potential of tryptophan metabolism in gut-brain signaling transduction: a narrative review.Journal of neuroinflammation · 2026Review
- Association between influenza A virus and SARS-CoV-2 infections and mood disorders.Brain, behavior, & immunity - health · 2026Article
- In silico discovery of natural compound-derived multi-target inhibitor for Huntington's disease therapy.Scientific reports · 2026Article
- Modulation of the Kynurenine Pathway: A New Approach for Treating Neurodegeneration.Life (Basel, Switzerland) · 2026Review
- Interaction of Hypoxia and Kynurenine Pathway in Periodontal Inflammation.International journal of tryptophan research : IJTR · 2026Article
- The tryptophan-kynurenine pathway in cardiovascular diseases: mechanistic insights and therapeutic opportunities.Frontiers in cardiovascular medicine · 2026Review
- Review
- Microbiota-Derived Tryptophan Metabolite Indole-3-Propionic Acid-Emerging Role in Neuroprotection.Molecules (Basel, Switzerland) · 2025Review
- Impact of gastrointestinal dysbiosis on tryptophan metabolism and neurological cancer progression.Medical oncology (Northwood, London, England) · 2025Review
- The Role of Pigments in Light Color Variation of the FireflyEcology and evolution · 2025Article
- Kynurenine Pathway Modulation by Exercise in Multiple Sclerosis: Implications for Neuroprotection and Inflammation.Cellular and molecular neurobiology · 2025Review
- The Kynurenine Pathway in Gut Permeability and Inflammation.Inflammation · 2025Review
- Serotonin dysfunction in ADHD.Journal of neurodevelopmental disorders · 2025Review
- Kynurenine Pathway in Epilepsy: Unraveling Its Role in Glutamate Excitotoxicity, GABAergic Dysregulation, Neuroinflammation, and Mitochondrial Dysfunction.Neurotoxicity research · 2025Review
- Diverse Physiological Roles of Kynurenine Pathway Metabolites: Updated Implications for Health and Disease.Metabolites · 2025Review
- KMO-driven metabolic reconfiguration and its impact on immune cell infiltration in nasopharyngeal carcinoma: a new avenue for immunotherapy.Cancer immunology, immunotherapy : CII · 2025Article
- Kynurenine pathway: a possible new mechanism for exercise in the prevention and treatment of Alzheimer's disease.Frontiers in aging neuroscience · 2025Review
- Effects of Ethanol Extract from Senna Leaf (EESL) on Inflammation and Oxidative Stress in Mice: A Non-targeted Metabolomic Study.Endocrine, metabolic & immune disorders drug targets · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Under normal physiological conditions, the kynurenine pathway (KP) plays a critical role in generating cellular energy and catabolizing tryptophan. Under inflammatory conditions, however, there is an upregulation of the KP enzymes, particularly kynurenine 3-monooxygenase (KMO). KMO has garnered much attention due to its production of toxic metabolites that have been implicated in many diseases and disorders. With many of these illnesses having an inadequate or modest treatment, there exists a need to develop KMO inhibitors that reduce the production of these toxic metabolites. Though prior efforts to find an appropriate KMO inhibitor were unpromising, the development of a KMO crystal structure has provided the opportunity for a rational structure-based design in the development of inhibitors. Therefore, the purpose of this review is to describe the kynurenine pathway, the kynurenine 3-monooxygenase enzyme, and KMO inhibitors and their potential candidacy for clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.